Activating Innate and Adaptive Immunity
Hiltonol® Immunotherapy for Cancer and Infectious Disease
Oncovir, Inc. is a Clinical Phase Biotechnology company dedicated to the development of Hiltonol® (Poly ICLC)
We promote Hiltonol® as drug product and vaccine adjuvant for oncology and infectious diseases
-
Oncovir Team
-
News & Media: The combination of poly-ICLC with an immunotherapy vaccine utilizing dendritic cells is a promising approach for treating patients with deadly brain cancer
-
Our Pipeline